New CEO David Ricks took over Lilly as the company continues to climb out of its post-Cymbalta/Zyprexa rut.
Easily the fastest grower in Merck’s portfolio, the oncology drug Keytruda is piling up dollars and indications at an impressive rate.
2017 is serving as another challenging year for Novartis as the company continues to work through the Gleevec/Glivec patent expirations that began in 2016, but management is confident that a new phase of growth will start in 2018.
Novo Nordisk executives believe that the company is on a path that will create growth in 2017 and beyond.
Pfizer is overcoming patent expirations by developing a steady new stream of products.
Roche’s Pharmaceuticals and Diagnostics Divisions continue to generate strong performances significantly driven by new product launches, including four new oncology treatments and the company’s first cancer immunotherapy medicine.
Sanofi executives continue to have faith in strategic plans to get the company to new heights despite continued impact from patent expirations.
Now on its seventh CEO in the last 10 years and in danger of losing its most valuable branded product, Teva is searching for answers.
HBA’s 2017 Annual Conference will be held in Philadelphia on Nov. 6-8, 2017.
A listing of the top 50 companies ranked by healthcare revenue.
